Study to Compare Conivaptan in Subjects With Mild & Moderate Liver Impairment Versus Subjects With Normal Liver Function

Inclusion Criteria: * Subjects with Normal Hepatic Function: * Weighs at least 45 kg * Body mass index between 18 and 40 kg/m2 inclusive * Must have normal hepatic function * Hepatic Impaired Subjects: * Weighs at least 45 kg * Meets criteria for mild or moderate hepatic impairment defined by Child-Pugh method * Body mass index between 18 and 40 kg/m2 inclusive Exclusion Criteria: * Subjects with Normal Hepatic Function: * Smokes more than 10 cigarettes per day * Known to be HIV positive or has HIV antibodies * Has clinically significant history or presence of illness, malignancy, or immunodeficiency * Is Hepatitis A, B, or C positive * Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration * History of substance abuse within 6 months prior to screening * Hepatic Impaired Subjects: * Has history or presence of biliary obstruction or biliary disease, hepatic encephalopathy, advanced acidities, portal hypertension, or biliary liver cirrhosis * Is hypovolemic or has evidence of orthostatic hypotension * Smokes more than 10 cigarettes per day * Known to be HIV positive or has HIV antibodies * Has clinically significant history or presence of illness, malignancy, or immunodeficiency * Has clinically significant history or presence of GI symptoms other than those associated with moderate hepatic impairment * Has had a blood transfusion or donated/lost more than 550ml of blood within 8 weeks of study drug administration * History of substance abuse within 6 months prior to screening